NPM1 and acute myeloid leukemia: We further evaluated the possible contribution of WT1 overexpression to the identification of risk groups that are typically stratified by genotypes such as the NPM1 or FLT3 mutation status, which are known molecular markers associated with the survival and treatment outcomes of the AML patients.